Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche par promoteur : gsk
gsk
MAJ Il y a 5 ans
A Double-Blind Extension of Protocol PAR 03
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
gsk
MAJ Il y a 5 ans
TZV Epidemiology Program of HSR and Rechallenge HSR: CHORUS
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
gsk
MAJ Il y a 5 ans
A double-blinded, randomized, placebo-controlled, staggered-parallel, escalating dose study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of subcutaneous injections of GSK 716155 in healthy volunteers
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
gsk
MAJ Il y a 5 ans
An open-label, drug interaction study of retigabine and lamotrigine in healthy male subjects
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
gsk
MAJ Il y a 5 ans
U0289-404: An Evaluator Blinded, 8 Week, Split Face Study to Evaluate and Compare the Efficacy and Tolerability of MAXCLARITYII and MURAD in Subjects with Acne
One of the main success factors in acne therapy is user compliance with treatment, product cost, availability and ease of use. Poor compliance may translate into decreased efficacy (either not improv...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
gsk
MAJ Il y a 5 ans
A randomized, double blind, placebo controlled cross over trial to compare valacyclovir HCl and acyclovir for suppression of subclinical herpes simplex virus sheddingExtensive searching has revealed that no clinical study report is available for this study
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
gsk
MAJ Il y a 5 ans
A multi-centre, randomised, double-blind (sponsor open), placebo-controlled, repeat dose, proof of mechanism study to evaluate the safety and tolerability, pharmacokinetics, pharmacodynamics and clinical efficacy of GSK3050002 in subjects with psoriatic arthritis
Chemokine (C-C motif) ligand 20 (CCL20) is a protein involved in attracting immune cells including subsets of T cells (for example Th17 cells), B cells, natural killer cells and dendritic cells to inf...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
gsk
MAJ Il y a 5 ans
A single-blind, randomized, multicentre, parallel group study to compare the efficacy and safety of Augmentin 500/125mg by mouth twice daily versus Cefaclor 250mg by mouth three times a day versus Cefuroxime 250mg by mouth twice daily in the treatment of acute exacerbations of chronic bronchitis in Chinese adult patients
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
gsk
MAJ Il y a 5 ans
An Open-label, Non-Comparative, Phase II Study of Topotecan as Single Agent, Second-Line Therapy Administered as a Continuous 21-Day Infusion Every 28 Days to Patients with Relapsed or Refractory Small Cell Lung Cancer
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
gsk
MAJ Il y a 5 ans
Study to assess immunogenicity and safety of GSK Biologicals’ investigational vaccination regimen administered concomitantly in separate injections with GSK Biologicals’ DTPa-IPV/Hib vaccine as a primary vaccination course to healthy infants at 2-4-6 months of age and as a booster dose at 12 to 18 months of age
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Précédent
1
2
3
4
5
6
7
8
9
10
Suivant